Gennaro Pagano
Group Leader and Expert Medical Director In Early Development Roche
Seminars
Wednesday 4th February 2026
Prasinezumab: Advancing Towards the First Disease Modifying Treatment for Parkinson’s Disease
9:45 am
- Demonstrating clinical potential of Prasinezumab to delay motor progression, highlighting meaningful functional benefit for patients
- Outlining α-synuclein targeting mechanism with supporting biomarker evidence to validate biological activity and translational relevance
- Exploring future Phase III directions and beyond to position Prasinezumab as a first-in-class disease-modifying therapy
VIRTUAL
